Pathogen-Reduced RBCs and the Red Cell Pathogen Inactivation (ReCePi) Study (26EL-630)

Please note: AABB reserves the right to make updates to this program.

• Educational Track: Scientific
• Topics: Blood Donation & Collection, Patient Transfusion
• Intended Audience: CEOs, COOs, Directors, Hospital Blood Banks, Hospitals, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Medical Directors, Nurses, Perfusionists, Physicians, Research Scientists, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
• Teaching Level: Intermediate

• Director/Moderator: Edward Yoon, MD, Subchief, Clinical Pathology, Medical Director, Transfusion Medicine, Kaiser Permanente Mid-Atlantic States, Rockville, MD
  Speaker: Mohamed Alsammak, MD, Medical Director, Transfusion Medicine, Director, Pathology Residency Program, Temple University Health System (Temple Health), Philadelphia, PA

• Program Description

  This program will introduce the subject and concepts behind pathogen-reduction technology applied to transfused red blood cell products (RBCs). The discussion will be centered around their use as part of the Red Cell Pathogen Inactivation (ReCePi) study, a multicenter initiative that investigated the safety and efficacy of pathogen-reduced RBCs in specific clinical settings, and the conclusions of its early investigations. With this context, currently ongoing and potential future applications for these blood products will be discussed.

  Learning Objectives

  After participating in this educational activity, participants should be able to:

  • Describe the process of pathogen-reduction of RBCs in the context of the ReCePi study.
  • Explain the goals and outcome of the initial limited trials of the ReCePi study.
  • Identify future potential clinical applications of pathogen-reduced RBCs.

  Registration

  Registration includes access to both the live and on-demand version of this eCast.

  If you are a facility interested in participating in this eCast, simply complete the Group Viewing registration form and AABB will provide detailed instructions to share with your team approximately one week prior to the live program (each team member to register for the program utilizing a promocode). For single viewers, simply click on the Register button below to register.

  Please note: registration for the live eCast will close 1 hour prior to the eCast start time. If you register after this time, you will receive access to the on-demand eCast when it is available.

  Single Viewer	Register
  Group Viewing	Register

  Continuing Education Credit

  This activity is eligible for one (1) continuing education credit/contact hour for Physicians, California Nurses, California Lab Personnel, Florida Lab Personnel and General Participation credit. AABB reserves the right to reduce or increase the number of credits granted based on the final activity duration. For more information on each credit type please visit our Continuing Education Credits webpage.

  There is no financial support for this activity.

  

  In support of improving patient care, this activity has been planned and implemented by the Association for the Advancement of Blood & Biotherapies (AABB), which is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

  Physicians (ACCME): AABB designates this live activity for a maximum of one (1) AMA PRA Category 1 Credit^TM. AABB designates this enduring activity for a maximum of one (1) AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  Claiming Credit
  Live Activity - Upon completion of the live activity, you will receive instructions to complete your evaluation, which is necessary to claim credit and receive your certificate of attendance/completion (credit must be claimed by the date provided in the instructions). The evaluation can be found by logging into the AABB Education Platform.

  Enduring Activity - Once the enduring (on-demand) program is available, you will receive instructions to access the AABB Education Platform. Upon completion of viewing the enduring activity, you will need to complete the evaluation, which is necessary to claim credit and receive your certificate of completion (credit must be claimed by the date provided in the AABB Education Platform).

  Program & Credit Expiration Dates:

  • Live Activity Program Date: May 6, 2026; Credit Expiration Date: June 6, 2026
  • Enduring Activity Program Dates: May 6, 2026 – May 5, 2029; Credit Expiration Date: May 5, 2029

  Disclosure Declaration

  It is the policy of the Association for the Advancement of Blood & Biotherapies to ensure independence, balance, objectivity, and scientific rigor and integrity in all of its CE activities. Faculty must disclose to the participants any relationships with commercial companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. AABB has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that the presence of such relationships will have a negative impact on the presentations.

  Disclosures for the planners of this event can be found here. Disclosures for the program faculty, peer reviewers, and AABB personnel are provided at the beginning of the program.

  Faculty Biography

  Dr. Mohammed Alsammak is the medical director of the blood bank within the Department of Pathology & Laboratory Medicine at Temple University Hospital in Philadelphia, PA. He is also an associate professor of pathology and laboratory medicine at the Lewis Katz School of Medicine at Temple University and is a teaching attending physician for the both the transfusion medicine/apheresis and hematopathology services. Dr. Alsammak was one of the site co-principal investigators for the Red Cell Pathogen Inactivation (ReCePi) Study at Temple University Hospital, which was among the initial participating sites.